Released Nov 10, 2022, after the close
10-Q filed Nov 10, 2022, 41 days after period end · 0000950170-22-024436
Q3 2022 · 10-Q
Revenue—
Net Income-$1.17M-$1.17M N/M vs Q3 2021N/M vs Q2 2022
EPS Diluted-$1.91-$1.91 N/M vs Q3 2021N/M vs Q2 2022
Operating Income-$1,199,464N/M
Operating Cash Flowderived-$1,731,418N/M
What the release said
The release
Same quarter
| Metric | Q3 2022 | Q3 2021 | Q3 2020 |
|---|---|---|---|
| Net Income | -$1.17M | -$3.04M | -$868.00 |
| EPS Diluted | -$1.91 | -$0.48 | $0.00 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Revelation Biosciences, Inc. · CIK 1810560 · Engraved from SEC EDGAR